Synergistic Activations of REG Iα and REG Iβ Promoters by IL-6 and Glucocorticoids through JAK/STAT Pathway in Human Pancreatic β Cells by Akiyo Yamauchi, Asako Itaya-Hironaka, Sumiyo Sakuramoto-Tsuchida, Maiko Takeda, Kiyomi Yoshimoto, Tomoko Miyaoka, Takanori Fujimura, Hiroki Tsujinaka, Chikatsugu Tsuchida, Hiroyo Ota, Shin Takasawa

“…Promoter assay revealed that a signal transducer and activator of transcription- (STAT-) binding site in each promoter of REG Iα (TGCCGGGAA) and REG Iβ (TGCCAGGAA) was essential for the IL-6+Dx-induced promoter activation. A Janus kinase 2 (JAK2) inhibitor significantly inhibited the IL-6+Dx-induced REG Iα and REG Iβ transcription. …”
Get full text

Longer-term safety and efficacy of baricitinib for atopic dermatitis in pediatric patients 2 to <18 years old: a randomized clinical trial of extended treatment to 3.6 years by Andreas Wollenberg, Masanori Ikeda, Chia-Yu Chu, Lawrence F. Eichenfield, Marieke M. B. Seyger, Apurva Prakash, Robinette Angle, Danting Zhu, Marco Pontes, Amy S. Paller

“…Background Baricitinib, an oral selective Janus kinase inhibitor, improved clinical signs and symptoms of moderate-to-severe atopic dermatitis (AD) at week 16 in the phase 3 pediatric study BREEZE-AD-PEDS.Objective To assess longer-term efficacy and safety of baricitinib in pediatric patients aged 2 to <18 years.Methods In BREEZE-AD-PEDS long-term extension, responders and partial responders (validated Investigator Global Assessment-Atopic Dermatitis [vIGA-AD®] 0/1/2) at Week 16 remained on double-blind treatment to which they were randomized (placebo, baricitinib [1-mg equivalent, 2-mg equivalent, or 4-mg equivalent); non-responders (vIGA-AD 3 or 4) at Week 16 transitioned to open-label baricitinib 4-mg equivalent. …”
Get full text

Serum Lipids Alterations in Patients Under Systemic JAK Inhibitors Treatments in Dermatology: Clinical Aspects and Management by Giovanni Paolino, Mario Valenti, Andrea Carugno, Matteo Bianco, Dario Didona, Matteo Riccardo Di Nicola, Pier Luigi Acutis, Carmen Cantisani, Vittoria Giulia Bianchi, Nicola Zerbinati, Alessandra Narcisi, Antonio Costanzo, Santo Raffaele Mercuri

“…<i>Background and Objectives</i>: Janus kinase inhibitors (JAKi) have significantly advanced the treatment of various dermatological conditions by modulating the JAK-STAT signalling pathway. …”
Get full text

Anticancer activity of Ilex khasiana, a rare and endemic species of holly in Northeast India, against murine lymphoma by Charles Lalnunfela, Pawi Bawitlung Lalthanpuii, Hmar Tlawmte Lalremsanga, Zothansiama, Chhaihlo Lalmuansangi, Mary Zosangzuali, Nachimuthu Senthil Kumar, Tochhawng Lalhriatpuii, Kholhring Lalchhandama

“…Molecular docking revealed high ligand binding ability of 2,6-di-tert-butylphenol to chemokine receptor CXCR4, DNA topoisomerase 2-alpha, DNA topoisomerase 2-beta, histone deacetylases (HDAC1, HDAC2, HDAC3), Janus kinase 1 and programmed cell death protein 1. …”
Get full text

Anisodamine ameliorates crystalline silica-exposed pulmonary inflammation and fibrosis via the α7nAChR/JAK2/STAT3 signaling pathway by Meng Liu, Hui Liu, Hong Kang, Juan Wu, Puhua Xing, Xiaorui Ding, Yangyang Wei, Xiaomei Kong

“…Further molecular investigations indicated a strong link between pulmonary inflammation and fibrosis, showing decreased levels of α7nAChR and increased expression of phosphorylated Janus kinase 2 (JAK2) and phosphorylated transcription factor 3 (STAT3) in the lung tissues of mice exposed to CS. …”
Get full text

Yoruba Epistemology, Art, Language and the Universe of Meanings: A Meta-Analysis by Michael O. Afolayan

“…It is a needed shock therapy, an organic rendition of an intellectual exposition of the Yoruba art. This commentary is janus-faced. On one hand, it looks at the unique way in which Moyo Okediji critiqued the work of Rowland Abiodun, Yoruba Art and Language: Seeking the African in African Art. …”
Get full text

Inhibition of triple-negative breast cancer growth via delphinidin-mediated suppression of the JAK2/STAT3/PD-L1 pathway by Xiaoping Yu, Xiaolong Song, Jiali Yan, Ziting Xiong, Lujie Zheng, Yan Luo, Fengcheng Deng, Yanfeng Zhu

“…Flow cytometry was employed to analyze programmed cell death-ligand 1 (PD-L1) and Cluster of Differentiation 69 expression, while Western blotting assessed the levels of PD-L1, Janus Kinase 2 (JAK2), Signal Transducer and Activator of Transcription 3 (STAT3), p-JAK2, p-STAT3, and exosomal marker proteins. …”
Get full text

Multicentre, 26-week, open-label phase 2 trial of the JAK inhibitor filgotinib in Behçet’s disease, idiopathic inflammatory myopathies and IgG4-related disease: DRIMID study protoc... by Sander W Tas, Joost Raaphorst, Paco M J Welsing, Jacob M van Laar, Rogier M Thurlings, Robbert J Goekoop, César Magro Checa, Jan A M van Laar, Bettina C Geertsema-Hoeve, Nicolle H Rekers, Erik Present

“…Given the activation of the type 1 interferon pathway in BD, IIM and IgG4-RD, inhibition of the Janus kinase (JAK) STAT pathway emerges as a promising therapeutic strategy. …”
Get full text

Switching to biological DMARDs versus cycling among JAK inhibitors in patients with rheumatoid arthritis and with inadequate response to JAK inhibitors: from FIRST registry by Yoshiya Tanaka, Hiroaki Tanaka, Satoshi Kubo, Shingo Nakayamada, Yusuke Miyazaki, Yoshino Inoue, Shunsuke Fukuyo, Ippei Miyagawa, Kentaro Hanami, Yasuyuki Todoroki, Masanobu Ueno, Yurie Satoh-Kanda, Ayako Yamaguchi

“…Objectives This study aimed to identify characteristics of patients with rheumatoid arthritis (RA) with an inadequate response to Janus kinase inhibitors (JAKi-IR) and evaluate the efficacy and safety of subsequent treatments.Methods This study included 434 patients with RA who started JAKi treatment. …”
Get full text

Disproportionality analysis of upadacitinib-related adverse events in inflammatory bowel disease using the FDA adverse event reporting system by Shiyi Wang, Xiaojian Wang, Jing Ding, Xudong Zhang, Hongmei Zhu, Yihong Fan, Changbo Sun

“…BackgroundUpadacitinib, a Janus kinase inhibitor, has been increasingly used over the past few years to treat moderate to severe ulcerative colitis and Crohn’s disease in patients who are insufficiently responsive or intolerant to tumor necrosis factor (TNF) antibodies, demonstrating notable clinical efficacy. …”
Get full text

Suberosin attenuates rheumatoid arthritis by repolarizing macrophages and inhibiting synovitis via the JAK/STAT signaling pathway by Huan Liu, Qianwei Li, Yuehong Chen, Min Dong, Hongjiang Liu, Jiaqian Zhang, Leiyi Yang, Geng Yin, Qibing Xie

“…The effect of SBR on the Janus kinase/signal transducer and activator of transcription (JAK/STAT) pathway was evaluated. …”
Get full text

Identification and functional analysis of hub genes involved in deoxynivalenol-induced enterotoxicity in porcine (Sus scrofa) by Jinhua He, Geng Zhao, Mingxia Chen, Ximing Ren, Peizhi Zhu, Zhizhong Liu, Jiayi Zhou, Hanwei Chen, Chuqiao Xiao, Xiang-Guang Li

“…Further analysis revealed that the up-regulated DEGs were enriched in tumor necrosis factor, nuclear factor kappa-B, mitogen-activated protein kinases, and Janus kinase/signal transducer and activator of transcription-related signaling pathways. …”
Get full text

An Analysis of the Effectiveness and Safety of Upadacitinib in the Treatment of Inflammatory Bowel Disease: A Multicenter Real-World Study by Hongzhen Wu, Tingting Xie, Qiao Yu, Tao Su, Min Zhang, Luying Wu, Xiaoling Wang, Xiang Peng, Min Zhi, Jiayin Yao

“…<b>Background and Aims:</b> Inflammatory bowel disease (IBD) requires effective treatment options. Upadacitinib, a Janus kinase 1 (JAK1) inhibitor, has shown effectiveness in trials for Crohn’s disease (CD) and ulcerative colitis (UC). …”
Get full text

Impact in Clinical Practice of the European Medicines Agency Health Alert About the Restriction of the Use of JAK Inhibitors by Elisabet Castañeda-Estévez, Cristina Vergara-Dangond, Martina Steiner, Maria Beatriz Paredes-Romero, Ana Esteban-Vázquez, Tatiana Cobo-Ibañez, Laura Trives-Folguera, Maria Liz Romero-Bogado, Isabel De La Cámara-Fernández, Patricia Richi-Alberti, Ana Acosta-Alfaro, Iría De la Osa-Subtil, Santiago Muñoz-Fernández

“…<b>Background/Objectives:</b> Janus kinase inhibitors (JAKi) have revolutionized the treatment of various inflammatory and immune disorders. …”
Get full text

Baricitinib treatment for hospitalized patients with severe COVID-19 on invasive mechanical ventilation: a propensity score-matched and retrospective analysis by Yanxiong Mao, Anyi Guo, Ying Zhang, Jianxing Lai, Dian Yuan, Hao Zhang, Wenqi Diao, Weisong Chen, Fugui Yan

“…IntroductionBaricitinib is a selective inhibitor of Janus kinase (JAK)1 and JAK2, which is associated with clinical improvement in non-severe COVID-19 patients. …”
Get full text

3D bioprinting of engineered exosomes secreted from M2-polarized macrophages through immunomodulatory biomaterial promotes in vivo wound healing and angiogenesis by Sayan Deb Dutta, Jeong Man An, Jin Hexiu, Aayushi Randhawa, Keya Ganguly, Tejal V. Patil, Thavasyappan Thambi, Jangho Kim, Yong-kyu Lee, Ki-Taek Lim

“…Our findings show that 3D-printed AGP hydrogel promoted M2 macrophage polarization by Janus kinase/signal transducer of activation (JAK/STAT), peroxisome proliferator-activated receptor (PPAR) signaling pathways and facilitated the M2-Exo secretion. …”
Get full text

miR-9-5p/HMMR regulates the tumorigenesis and progression of clear cell renal cell carcinoma through EMT and JAK1/STAT1 signaling pathway by Xinyang Niu, Dingheng Lu, Weitao Zhan, Jiazhu Sun, Yuxiao Li, Yuchen Shi, Kai Yu, Suyuelin Huang, Xueyou Ma, Xiaoyan Liu, Ben Liu

“…HMMR might influence ccRCC growth via the Epithelial-Mesenchymal Transition (EMT) pathway and the Janus Kinase 1/Signal Transducer and Activator of Transcription 1 (JAK1/STAT1) pathway. …”
Get full text

Hepatocyte-derived liver progenitor-like cells attenuate liver cirrhosis via induction of apoptosis in hepatic stellate cells by Xu Zhou, Wen-Ming Liu, Han-Yong Sun, Yuan Peng, Ren-Jie Huang, Cai-Yang Chen, Hong-Dan Zhang, Shen-Ao Zhou, Hong-Ping Wu, Dan Tang, Wei-Jian Huang, Han Wu, Qi-Gen Li, Bo Zhai, Qiang Xia, Wei-Feng Yu, He-Xin Yan

“…Furthermore, synergistic effects between amphiregulin and FGF19 within HepLPC-secretomes were identified, contributing to HSC apoptosis and exerting antifibrotic effects via activation of the janus kinase-STAT1 pathway. Conclusions:. HepLPCs have the potential to ameliorate liver cirrhosis by inducing STAT1-dependent apoptosis in HSCs. …”
Get full text

Monocyte STAT1 phosphorylation and treatment response of JAK inhibitors in chronic nonbacterial osteomyelitis by Motoshi Sonoda, Keishiro Kinoshita, Nobutaka Harada, Sungyeon Park, Shunichi Adachi, Yutaro Yada, Katsuhide Eguchi, Toshifumi Fujiwara, Makiko Kido-Nakahara, Noriko Kinjo, Masataka Ishimura, Shouichi Ohga

“…The early diagnosis and management are challenging due to the lack of reliable diagnostic markers and the occasional intractable cases despite conventional anti-inflammatory treatments. Janus kinase (JAK) inhibitors have recently shown potential utility; however, reports on their use for pediatric patients with CNO remain limited, and no established biomarkers exist to monitor disease activity. …”
Get full text

Successful Achievement of Demanding Outcomes in Upadacitinib-Treated Atopic Dermatitis Patients: A Real-World, 96-Week Single-Centre Study by Stamatios Gregoriou, Ioannis-Alexios Koumprentziotis, Ileana Afroditi Kleidona, Michail Bakakis, Eleni Hatzidimitriou, Theodora Douvali, Aikaterini Tsiogka, Styliani Mastraftsi, Aristeidis Vaiopoulos, Alexander Stratigos

“…Abstract Introduction Results from randomized controlled trials of upadacitinib, a Janus kinase (JAK) inhibitor, have led to its approval for the treatment of moderate-to-severe atopic dermatitis (AD) in patients aged ≥ 12 years. …”
Get full text